Related Experiment Video

Updated: Oct 27, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K

Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms

Mandeep Dahiya1, Harish Dureja1

  • 1Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India.

Journal of Chemotherapy (Florence, Italy)
|July 22, 2021
PubMed

Insights

Hepatocellular carcinoma (HCC) is a deadly cancer resistant to treatment. Understanding sorafenib resistance mechanisms and identifying predictive biomarkers are crucial for developing effective HCC therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high mortality and resistance to conventional therapies.
  • Sorafenib, a multi-kinase inhibitor, is a standard treatment for unresectable HCC, but its precise mechanisms of action and the development of resistance require further elucidation.

Purpose of the Study:

  • To explore the molecular mechanisms underlying sorafenib resistance in HCC.
  • To identify potential predictive biomarkers for sorafenib resistance.
  • To discuss current and future therapeutic strategies for HCC management.

Main Methods:

  • Review of molecular concepts related to HCC progression and sorafenib resistance.
  • Analysis of potential molecular targets for HCC therapy.
  • Discussion of advancements in biomarker-driven treatment strategies.

Main Results:

  • Genetic heterogeneity is a key factor in the development of sorafenib resistance.
  • Understanding resistance mechanisms is essential for improving therapeutic outcomes.
  • Biomarker-driven strategies hold promise for personalized HCC treatment.

Conclusions:

  • Further research into sorafenib resistance mechanisms is critical for advancing HCC treatment.
  • Development and implementation of predictive biomarkers are necessary for effective therapeutic strategies.
  • Future advancements may lead to innovative targeted therapies for HCC.
Keywords:
HCCcombination therapygene mutationsresistancesorafenibtherapeutic targets

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K